137644-94-1Relevant articles and documents
FXR receptor agonist
-
, (2019/02/10)
The present invention discloses an FXR receptor agonist, belongs to the technical field of medicine, and particularly relates to a compound represented by a formula (I), a pharmaceutically acceptablesalt, an ester or a stereoisomer thereof, wherein R, R, R, M, L, L1, W, A , B, Q, m and n are defined in the specification. The present invention further relates to a preparation method of the compound, a pharmaceutical preparation, and applications in preparation of drugs for treatment and/or prevention of nonalcoholic fatty liver disease, primary biliary cirrhosis, lipid metabolism disorder, diabetic complication, malignant tumors and other related diseases mediated by FXR receptors. The formula I is defined in the specification.
Pseudoguaianolides from Intramolecular Cycloadditions of Aryl Diazoketones: Synthesis of (+/-)-Confertin and an Approach to the Synthesis of (+/-)-Damsin
Kennedy, Michael,McKervey, M. Anthony
, p. 2565 - 2574 (2007/10/02)
Rhodium(II) mandelate-catalysed cyclisation of α-diazoketones derived from 3-arylpropionic acids produces bicyclodecatrienones, one of which has been used to synthesise an advanced (+/-)-confertin intermediate in six stages and 20percent overall yield.The possibility of constructing intermediates for the synthesis of damsin-like pseudoguaianolides via catalysed diazoketone cyclisation is also examined and methods for the construction of polyfunctional 3-arylpropionic acids suitable for use as damsin precursors are presented.